Skip to content
Screener

Veracyte VCYT Intangibles (Net)

Intangibles (Net) at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$145.7M-43.4%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$2.98M-38.8%
Castle Biosciences logo
Castle BiosciencesCSTL
$86.66M+28.9%
Guardant Health logo
Guardant HealthGH
$4.71M-25.0%
Natera, Inc. logo
Natera, Inc.NTRA
$360.2M
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$166.8M+73.8%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.8B+72.4%
Enterprise value$3.57B+75.8%
P/E43.1×-40.5×
P/S+2.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemMarch 31, 2026 / Gross Carrying AmountMarch 31, 2026 / Accumulated AmortizationMarch 31, 2026 / Net Carrying AmountDecember 31, 2025 / Gross Carrying AmountDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Net Carrying AmountWeighted Average Remaining Amortization Period (Years)
Percepta product technology$16,000$(11,733)$4,267$16,000$(11,467)$4,5334
Prosigna product technology4,120(1,740)2,3804,120(1,671)2,4498.7
Decipher product technology97,300(45,930)51,37097,300(43,558)53,7426.3
Decipher trade names4,000(4,000)4,000(3,843)157
C2i developed technology25,300(3,654)21,64625,300(3,233)22,06712.8
Total finite-lived intangibles146,720(67,057)79,663146,720(63,772)82,9488.0
In-process research and development6,2006,2006,2006,200
Total intangible assets$152,920$(67,057)$85,863$152,920$(63,772)$89,148

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's intangibles (net)?
Veracyte (VCYT) reported intangibles (net) of $79.66M in Q1 2026.
How has Veracyte's intangibles (net) changed year-over-year?
Veracyte's intangibles (net) decreased by 6.9% year-over-year, from $85.59M to $79.66M.
What is the long-term trend for Veracyte's intangibles (net)?
Over 5 years (2020 to 2025), Veracyte's intangibles (net) has grown at a 6.7% compound annual growth rate (CAGR), from $59.92M to $82.95M.
What does intangibles (net) mean?
Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.

Ask your AI about Veracyte's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude